Imaging of Cell Proliferation: Status and Prospects
暂无分享,去创建一个
[1] E. Cronkite,et al. The metabolism and fate of tritiated thymidine in man. , 1960, The Journal of clinical investigation.
[2] J. Cleaver. Thymidine metabolism and cell kinetics , 1967 .
[3] A. Wolf,et al. Detection of DNA synthesis in intact organisms with positron-emitting (methyl- 11 C)thymidine. , 1972, Proceedings of the National Academy of Sciences of the United States of America.
[4] P. Hauschka. Analysis of nucleotide pools in animal cells. , 1973, Methods in cell biology.
[5] P. Hauschka. Chapter 19 Analysis of Nucleotide Pools in Animal Cells , 1974 .
[6] R. Then,et al. Thymidine concentrations in serum and urine of different animal species and man. , 1977, Biochemical pharmacology.
[7] H. Atkins,et al. Scintigraphy with positron-emitting compounds.--I. Carbon-11 labeled thymidine and thymidylate. , 1978, International journal of nuclear medicine and biology.
[8] C. Cass,et al. Transport of nucleoside drugs in animal cells. , 1981, Pharmacology & therapeutics.
[9] S M Larson,et al. Positron imaging feasibility studies. I: Characteristics of [3H]thymidine uptake in rodent and canine neoplasms: concise communication. , 1981, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] D. Brooks,et al. Measurement of Regional Cerebral pH in Human Subjects Using Continuous Inhalation of 11CO2 and Positron Emission Tomography , 1984, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[11] P. Conti,et al. Selective alkylation of pyrimidyl-dianions: synthesis and purification of 11C labeled thymidine for tumor visualization using positron emission tomography , 1984 .
[12] N. M. Alpert,et al. Measurement of Brain pH Using 11CO2 and Positron Emission Tomography , 1984, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[13] S M Larson,et al. Short-term thymidine uptake in normal and neoplastic tissues: studies for PET. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] Selective alkylation of pyrimidyldianions: synthesis and purification of 11C labeled thymidine for tumor visualization using positron emission tomography. , 1984, The International journal of applied radiation and isotopes.
[15] T. Chou,et al. Synthesis and biological effects of 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil , 1987, Antimicrobial Agents and Chemotherapy.
[16] A. Shields,et al. Cellular sources of thymidine nucleotides: studies for PET. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] J. Sherley,et al. Regulation of human thymidine kinase during the cell cycle. , 1988, The Journal of biological chemistry.
[18] P. Martiat,et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] S. Pauwels,et al. Noninvasive measurement of liver regeneration with positron emission tomography and [2-11C]thymidine. , 1991, Gastroenterology.
[20] S. Pauwels,et al. Production of [2-11C]thymidine for quantification of cellular proliferation with PET. , 1991, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.
[21] B. Oberg,et al. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. , 1991, Biochemical and biophysical research communications.
[22] S. Eriksson,et al. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. , 1991, The Journal of biological chemistry.
[23] J B Bassingthwaighte,et al. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] R L Wahl,et al. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] H. Miyazawa,et al. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] R. Blasberg,et al. Iododeoxyuridine uptake and retention as a measure of tumor growth. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] F Daghighian,et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] T. Borght,et al. Brain tumor imaging with PET and 2-[carbon-11]thymidine. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] D. Wong,et al. High performance liquid chromatography of carbon-11 labeled thymidine and its major catabolites for clinical PET studies. , 1994, Nuclear medicine and biology.
[30] H. Joensuu,et al. Imaging of head and neck tumors with positron emission tomography and [11C]methionine. , 1994, International journal of radiation oncology, biology, physics.
[31] P. Goethals,et al. Measurement of [methyl-carbon-11]thymidine and its metabolites in head and neck tumors. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] B. Glimelius,et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] P. Conti,et al. Synthesis of 2'-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. , 1995, Nuclear medicine and biology.
[34] H. Thierens,et al. Kinetics of [methyl-11C]thymidine in patients with squamous cell carcinoma of the head and neck. , 1996, Acta oncologica.
[35] A. Shields,et al. Development of labeled thymidine analogs for imaging tumor proliferation. , 1996, Nuclear medicine and biology.
[36] D. Mankoff,et al. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] S. Eriksson,et al. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity , 1996, Antimicrobial agents and chemotherapy.
[38] G. van Kaick,et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[39] J. Koudstaal,et al. Proliferative activity in human brain tumors: comparison of histopathology and L-[1-(11)C]tyrosine PET. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] M. Bergström,et al. In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[41] Otto Muzik,et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.
[42] R. Finn,et al. Radiosynthesis and quality assurance of 5-[124I]Iodo-2'-deoxyuridine for functional PET imaging of cell proliferation. , 1998, Nuclear medicine and biology.
[43] T K Lewellen,et al. Carbon-11-thymidine and FDG to measure therapy response. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[44] D. Mankoff,et al. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] H. Sakahara,et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[46] M. Berger,et al. 2-[C-11]thymidine imaging of malignant brain tumors. , 1999, Cancer research.
[47] N. Kuwata,et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining , 1999, Neurosurgical Review.
[48] M. Bergström,et al. Elimination of nonspecific radioactivity from [76Br]bromide in PET study with [76Br]bromodeoxyuridine. , 1999, Nuclear medicine and biology.
[49] H. Lyng,et al. Measurement of proliferation activity in human melanoma xenografts by magnetic resonance imaging. , 1999, Magnetic resonance imaging.
[50] G. Bormans,et al. The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma , 1999, Cancer.
[51] R. Blasberg,et al. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. , 2000, Cancer research.
[52] M. Bergström,et al. Synthesis of [76Br]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[53] Johannes Gerdes,et al. The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.
[54] A general method to correct PET data for tissue metabolites using a dual-scan approach. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[55] W. Vaalburg,et al. Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[56] A. Shields,et al. Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. , 2000, Nuclear medicine and biology.
[57] J. Bading,et al. Pharmacokinetics of the thymidine analog 2'-fluoro-5-[(14)C]-methyl-1-beta-D-arabinofuranosyluracil ([(14)C]FMAU) in rat prostate tumor cells. , 2000, Nuclear medicine and biology.
[58] M. Bergström,et al. Analysis of 76Br-BrdU in DNA of brain tumors after a PET study does not support its use as a proliferation marker. , 2001, Nuclear medicine and biology.
[59] Jae Jeong,et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[60] M J Welch,et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. , 2001, Nuclear medicine and biology.
[61] V. Grégoire,et al. Use of 5-[76Br]bromo-2'-fluoro-2'-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model , 2001, European Journal of Nuclear Medicine and Molecular Imaging.
[62] Hui Wang,et al. Radiolabeled 2′-fluorodeoxyuracil-β-D-arabinofuranoside (FAU) and 2′-fluoro-5-methyldeoxyuracil-β-D-arabinofuranoside (FMAU) as tumor-imaging agents in mice , 2002, Cancer Chemotherapy and Pharmacology.
[63] Torsten Mattfeldt,et al. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. , 2002, Cancer research.
[64] A. Feldman,et al. Noninvasive fluorescent imaging reliably estimates biomass in vivo. , 2002, BioTechniques.
[65] F. O’Sullivan,et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis. , 2002, Molecular imaging.
[66] Hui Wang,et al. Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. , 2002, Cancer chemotherapy and pharmacology.
[67] Bengt Långström,et al. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[68] O. Muzik,et al. Kinetics of 3'-deoxy-3'-[F-18]fluorothymidine uptake and retention in dogs. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[69] H. Dittmann,et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[70] Mark Muzi,et al. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[71] F. O’Sullivan,et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. , 2002, Molecular imaging.
[72] S. Gambhir,et al. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.
[73] Chun Li,et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. , 2003, Cancer research.
[74] D. Visvikis,et al. Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[75] Torsten Mattfeldt,et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[76] Y. Yonekura,et al. Development of radioiodinated nucleoside analogs for imaging tissue proliferation: comparisons of six 5-iodonucleosides. , 2003, Nuclear medicine and biology.
[77] Qimin He,et al. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. , 2003, Cancer research.
[78] A. Shields,et al. Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. , 2003, Nuclear medicine and biology.
[79] Ingeborg Goethals,et al. Nuclear medicine imaging to predict response to radiotherapy: a review. , 2003, International journal of radiation oncology, biology, physics.
[80] Roger N Gunn,et al. 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. , 2003, Journal of the National Cancer Institute.
[81] V. Raman,et al. Real time non‐invasive imaging of receptor–ligand interactions in vivo , 2003, Journal of cellular biochemistry.
[82] A. Harris,et al. Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. , 2004, Biochimica et biophysica acta.
[83] J. Baak,et al. Prognostic value of proliferation in invasive breast cancer: a review , 2004, Journal of Clinical Pathology.
[84] Y. Yonekura,et al. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. , 2004, Nuclear medicine and biology.
[85] Jae Seung Kim,et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[86] G. Sevlever,et al. Characterization of brain tumors by MRS, DWI and Ki-67 labeling index , 2005, Journal of Neuro-Oncology.
[87] H. Schirrmeister,et al. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? , 2004, The Journal of thoracic and cardiovascular surgery.
[88] D. Visvikis,et al. Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[89] H. Groen,et al. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[90] A. van Waarde,et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[91] W. Vaalburg,et al. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[92] D. Lee,et al. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer , 2004, Nuclear medicine communications.
[93] J. Bading,et al. Pharmacokinetics of the thymidine analog 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats. , 2004, Nuclear medicine and biology.
[94] J. Pruim,et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[95] O. Muzik,et al. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[96] T. Mattfeldt,et al. Clinical relevance of imaging proliferative activity in lung nodules , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[97] H. Sakahara,et al. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[98] O. Muzik,et al. Biodistribution and radiation dosimetry estimates of 1-(2'-deoxy-2'-(18)F-Fluoro-1-beta-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[99] David A Mankoff,et al. PET imaging of cellular proliferation. , 2005, Radiologic clinics of North America.
[100] Michael E Phelps,et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[101] Mark Muzi,et al. Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[102] Michael E. Phelps,et al. Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2005, Molecular Imaging and Biology.
[103] E. Aboagye,et al. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. , 2005, Cancer research.
[104] Marvin Bergsneider,et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[105] S. Shousha,et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. , 2005, Cancer research.
[106] J. Wesseling,et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[107] C Sotiriou,et al. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[108] Otto Muzik,et al. A simplified analysis of [18F]3′-deoxy-3′-fluorothymidine metabolism and retention , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[109] Mark Muzi,et al. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[110] Karl Herholz,et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[111] O. Muzik,et al. Imaging DNA synthesis in vivo with 18F-FMAU and PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[112] K. Ishiwata,et al. Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[113] Jun Toyohara,et al. Evaluation of 4'-[methyl-14C]thiothymidine for in vivo DNA synthesis imaging. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[114] H. Hoekstra,et al. Positron emission tomography in patients with breast cancer using (18)F-3'-deoxy-3'-fluoro-l-thymidine ((18)F-FLT)-a pilot study. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[115] Mark Muzi,et al. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[116] Michael E Phelps,et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. , 2006, Chest.
[117] Paul Workman,et al. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. , 2006, Cancer research.
[118] Vyacheslav Kalchenko,et al. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. , 2006, Cancer research.
[119] Jeffrey S Armstrong,et al. Mitochondria: a target for cancer therapy , 2006, British journal of pharmacology.
[120] T. Mattfeldt,et al. Molecular imaging of proliferation in malignant lymphoma. , 2006, Cancer research.
[121] T. Naruke,et al. Fluorodeoxyglucose Positron Emission Tomography Can Predict Pathological Tumor Stage and Proliferative Activity Determined by Ki-67 in Clinical Stage IA Lung Adenocarcinomas , 2006 .
[123] Tim A D Smith,et al. [Methyl-3H]-choline incorporation into MCF-7 cells: correlation with proliferation, choline kinase and phospholipase D assay. , 2007, Anticancer research.
[124] Falko Fend,et al. Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma , 2007, Clinical Cancer Research.
[125] Y. Nishiyama,et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[126] Detection of locally advanced gastric cancer with Fluoro-18-thymidine and Fluoro-18-fluorodeoxyglucose positron emission tomography , 2007 .
[127] Characterization and response monitoring for aggressive non-Hodgkin's lymphoma using 18F-fluoro-deoxythymidine PET/CT , 2007 .
[128] R. Grundy,et al. Magnetic resonance spectroscopy suggests key differences in the metastatic behaviour of medulloblastoma. , 2007, European journal of cancer.
[129] Mitchel S Berger,et al. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. , 2007, Journal of neurosurgery.
[130] I. Buvat,et al. Partial-Volume Effect in PET Tumor Imaging* , 2007, Journal of Nuclear Medicine.
[131] O. Muzik,et al. Tumor Imaging Using 1-(2′-deoxy-2′-18F- Fluoro-β-d-Arabinofuranosyl)Thymine and PET , 2007, Journal of Nuclear Medicine.
[132] Eric O. Aboagye,et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[133] W. Oyen,et al. 18F-FLT PET Does Not Discriminate Between Reactive and Metastatic Lymph Nodes in Primary Head and Neck Cancer Patients , 2007, Journal of Nuclear Medicine.